SciClone Pharmaceuticals (Holdings) Limited announced that the Phase III clinical trial (the "Trial") of Vaborem® (Meropenem and Vaborbactam for injection) ("Vaborem®"), a new antibacterial drug, has completed subject enrollment in China. This study is a Phase III, randomized, double-blind, double-dummy, active-controlled, multi-center clinical trial being conducted in China to evaluate the efficacy and safety of Vaborem® for patients with complicated urinary tract infections ("cUTI") including pyelonephritis. Led by Principal Investigators Professor Wang Minggui from Huashan Hospital affiliated to Fudan University and Professor Zheng Junhua from Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, the Trial includes 108 subjects across 27 clinical trial sites throughout China.

The results of this study and a concurrent study in healthy volunteers in China to evaluate the pharmacokinetic profile of Vaborem®, are meant to bridge the foreign clinical trial data and eventually support the New Drug Application ("NDA") of Vaborem® in China. Vaborem® is a fixed-dose combination of a carbapenem and a novel boronic acid -lactamase inhibitor of class A and Class C serine -lactamase. Vaborbactam can inhibit various class A and class C -lactamases, so it protects meropenem from degradation by serine carbapenemases, restoring meropenem's activity against carbapenem-resistant strains.

Vaborem® has been specifically developed to inhibit carbapenem-resistant enterobacterales ("CRE") including the commonly found Klebsiella pneumoniae carbapenemase ("KPC")- producing bacteria. Currently, Vaborem® has been approved in the European Union for the treatments of a variety of indications including cUTI, complicated intra-abdominal infections ("cIAI") and hospital-acquired pneumonia ("HAP") and has been approved in the United States of America for the treatment of cUTI. Pursuant to the License and Collaboration Agreement entered into between SciClone Pharmaceuticals and A. Menarini Asia-Pacific Holdings Pte.

Ltd., part of The Menarini Group ("Menarini"), in August 2022, the Company has the exclusive right to develop and commercialize Vaborem® in China, under Menarini's head license agreement with Melinta Therapeutics Inc. In March 2023, the National Medical Products Administration (the "NMPA") in China officially approved the Company's Investigational New Drug (the "IND") application for Vaborem®. In July 2023, the first subject was dosed in the Trial. The successful completion of the Trial subject enrollment for Vaborem® in China marks another important milestone in the clinical development progress of Vaborem®, reaffirming the strength of SciClone's clinical development team.

The Company sincerely thanks every investigator and patient involved in the Trial, as well as it collaborating partners, and look forward to providing more effective and safer treatment options as soon as possible for patients in China suffering from life threatening and multidrug-resistant infections.